# | Title | Journal | Year | Citations |
---|
1 | EUCAST expert rules in antimicrobial susceptibility testing | Clinical Microbiology and Infection | 2013 | 527 |
2 | The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee | Clinical Microbiology and Infection | 2017 | 428 |
3 | Development of the quinolones | Journal of Antimicrobial Chemotherapy | 2003 | 393 |
4 | Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis | Clinical Infectious Diseases | 2006 | 270 |
5 | The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach | Clinical Microbiology and Infection | 2012 | 232 |
6 | Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Journal of Antimicrobial Chemotherapy | 2003 | 189 |
7 | European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing | Clinical Microbiology and Infection | 2006 | 176 |
8 | Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests | Journal of Antimicrobial Chemotherapy | 2001 | 166 |
9 | Fluoroquinolone Antibiotics | Drugs | 1988 | 141 |
10 | Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme | Journal of Antimicrobial Chemotherapy | 2004 | 126 |
11 | Rapid Identification of Major Escherichia coli Sequence Types Causing Urinary Tract and Bloodstream Infections | Journal of Clinical Microbiology | 2015 | 121 |
12 | ACTIVITY OF VARIOUS ANTIMICROBIAL AGENTS AGAINST L MONOCYTOGENES | Lancet, The | 1990 | 103 |
13 | Continuous Infusion of ??-Lactam Antibiotics | Clinical Pharmacokinetics | 1998 | 91 |
14 | Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06 | Journal of Antimicrobial Chemotherapy | 2008 | 86 |
15 | Tigecycline pharmacokinetic/pharmacodynamic update | Journal of Antimicrobial Chemotherapy | 2008 | 80 |
16 | Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model | Antimicrobial Agents and Chemotherapy | 2003 | 72 |
17 | Theatre over-shoes do not reduce operating theatre floor bacterial counts | Journal of Hospital Infection | 1991 | 69 |
18 | Mupirocin-resistant Staphylococcus aureus | Lancet, The | 1990 | 66 |
19 | Growth in the use of antibiotics in the community in England and Scotland in 1980-93 | BMJ: British Medical Journal | 1996 | 66 |
20 | The effect of surgical approach on blood flow to the femoral head during resurfacing | Journal of Bone and Joint Surgery: British Volume | 2007 | 64 |
21 | Interactions between aminoglycoside antibiotics and carbenicillin or ticarcillin | Infection | 1976 | 62 |
22 | Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06 | Journal of Antimicrobial Chemotherapy | 2008 | 62 |
23 | A review of the pharmacokinetics and pharmacodynamics of aztreonam | Journal of Antimicrobial Chemotherapy | 2016 | 61 |
24 | A systematic review of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry compared to routine microbiological methods for the time taken to identify microbial organisms from positive blood cultures | European Journal of Clinical Microbiology and Infectious Diseases | 2015 | 57 |
25 | Fosfomycin trometamol | Journal of Antimicrobial Chemotherapy | 1994 | 55 |
26 | Mupirocin-resistant Staphylococcus aureus | Lancet, The | 1992 | 54 |
27 | Typing of Listeria spp. by random amplified polymorphic DNA (RAPD) analysis | Journal of Medical Microbiology | 1993 | 54 |
28 | Listeria faecal carriage by renal transplant recipients, haemodialysis patients and patients in general practice: its relation to season, drug therapy, foreign travel, animal exposure and diet | Epidemiology and Infection | 1991 | 53 |
29 | The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosaassessed by combining antibiotic exposure and bacterial susceptibility | Journal of Antimicrobial Chemotherapy | 1999 | 52 |
30 | Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models | International Journal of Antimicrobial Agents | 2002 | 51 |
31 | Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service | Journal of Antimicrobial Chemotherapy | 2010 | 49 |
32 | The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens | Journal of Antimicrobial Chemotherapy | 2000 | 47 |
33 | The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials | Journal of Antimicrobial Chemotherapy | 1986 | 46 |
34 | Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial | Expert Opinion on Investigational Drugs | 1999 | 45 |
35 | The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments | International Journal of Antimicrobial Agents | 2015 | 45 |
36 | Population structure ofEscherichia colicausing bacteraemia in the UK and Ireland between 2001 and 2010 | Journal of Antimicrobial Chemotherapy | 2016 | 45 |
37 | The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline | Journal of Antimicrobial Chemotherapy | 1988 | 44 |
38 | In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci | Journal of Antimicrobial Chemotherapy | 1999 | 44 |
39 | Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory | International Journal of Antimicrobial Agents | 2006 | 44 |
40 | Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06 | Journal of Antimicrobial Chemotherapy | 2008 | 42 |
41 | Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy | Journal of Antimicrobial Chemotherapy | 1993 | 41 |
42 | Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes | Journal of Antimicrobial Chemotherapy | 2008 | 41 |
43 | Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae | Antimicrobial Agents and Chemotherapy | 2012 | 41 |
44 | Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group | Clinical Infectious Diseases | 2018 | 40 |
45 | Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty | Journal of Antimicrobial Chemotherapy | 1990 | 39 |
46 | In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics | Clinical Microbiology and Infection | 1999 | 39 |
47 | AAC(1): a new aminoglycoside-acetylating enzyme modifying the Cl aminogroup of apramycin | Journal of Antimicrobial Chemotherapy | 1987 | 37 |
48 | Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam | British Journal of Urology | 1995 | 36 |
49 | The use and therapeutic drug monitoring of teicoplanin in the UK | Clinical Microbiology and Infection | 2004 | 36 |
50 | Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections | Antimicrobial Resistance and Infection Control | 2018 | 34 |